Drugs / 177Lu-AB-3PRGD2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05013086 | Oct 2021 → Oct 2024 | — | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06375564 | Jun 2024 → Dec 2025 overdue | refractory malignant neoplasm | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-AB-3PRGD2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05013086 ↗ |
| Route | Intravenous | “accepted intravenous injection of 177Lu-AB-3PRGD2” NCT05013086 ↗ |